Jane Street’s Y-mAbs Therapeutics YMAB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-60,873
Closed -$275K 11931
2025
Q2
$275K Buy
+60,873
New +$274K ﹤0.01% 8010
2025
Q1
Sell
-33,203
Closed -$260K 10815
2024
Q4
$260K Buy
33,203
+14,267
+75% +$174K ﹤0.01% 7962
2024
Q3
$249K Sell
18,936
-63,023
-77% -$799K ﹤0.01% 8331
2024
Q2
$990K Sell
81,959
-18,559
-18% -$251K ﹤0.01% 5795
2024
Q1
$1.63M Buy
100,518
+68,230
+211% +$920K ﹤0.01% 4493
2023
Q4
$220K Buy
+32,288
New +$187K ﹤0.01% 8068
2023
Q3
Sell
-40,195
Closed -$273K 9521
2023
Q2
$273K Buy
40,195
+15,930
+66% +$119K ﹤0.01% 7269
2023
Q1
$122K Sell
24,265
-42,386
-64% -$173K ﹤0.01% 8120
2022
Q4
$325K Buy
66,651
+54,276
+439% +$394K ﹤0.01% 6880
2022
Q3
$178K Buy
+12,375
New +$205K ﹤0.01% 8282
2022
Q1
Sell
-44,673
Closed -$724K 11128
2021
Q4
$724K Buy
44,673
+26,362
+144% +$563K ﹤0.01% 6571
2021
Q3
$523K Buy
+18,311
New +$577K ﹤0.01% 7197
2021
Q2
Sell
-7,204
Closed -$218K 10515
2021
Q1
$218K Sell
7,204
-13,403
-65% -$549K ﹤0.01% 8147
2020
Q4
$1.02M Buy
20,607
+11,743
+132% +$543K ﹤0.01% 4626
2020
Q3
$340K Buy
8,864
+1,707
+24% +$67.9K ﹤0.01% 5703
2020
Q2
$309K Buy
+7,157
New +$271K ﹤0.01% 5793

Other funds holding YMAB

Jane Street's YMAB Position: Q3 2025 in Review

Jane Street sold out of Y-mAbs Therapeutics (YMAB) in Q3 2025, closing a stake of 60,873 shares — an estimated $275K sold.

Jane Street first reported a position in YMAB in Q2 2020 and held it in 16 quarters. The position peaked at $1.63M in Q1 2024. 2 funds tracked by Wall St. Rank hold YMAB as of Q3 2025.

  • Jane Street reported no remaining Y-mAbs Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Jane Street sold 60,873 Y-mAbs Therapeutics shares in Q3 2025, an estimated $275K.
  • Jane Street first reported a position in Y-mAbs Therapeutics in Q2 2020 and held it in 16 quarters.
  • Jane Street's Y-mAbs Therapeutics position peaked at $1.63M in Q1 2024.
  • 2 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2025.

Based on Jane Street's 13F filing for Q3 2025, filed 14 Nov 2025.